Veronica Hackethal, MD
Selexipag Delays PAH Progression in Patients with Connective Tissue Disease
Results of a subgroup analysis from the GRIPHON trial are promising for a hard-to-treat population.
New Biomarker Could Improve ARDS, AHF Diagnosis
A biomarker of myocardial strain and inflammation may be able to discriminate between two similar pulmonary emergencies.
Quiz: 2017 ACC/AHA/HFSA Update to 2013 HF Guidelines
Test your recall of the most recent amendments to the heart failure guidelines on prevention, treatment of hypertension, and comorbidities.
Methamphetamine-associated PAH: First Prospective Cohort Study
Methamphetamine abuse is on a steady rise in the US. A new study highlights the nature and dangers of Meth-PAH.
Hellenic Heart Failure Study: Impact of Mediterranean Diet on Recurrent ACS
Results of this study suggest a role for the anti-inflammatory diet in secondary prevention.
Toward Improved Risk Stratification in Pulmonary Arterial Hypertension
A new study supports the utility of pulmonary arterial proportional pulse pressure to predict 5-year mortality in patients with PAH.
How Dangerous is Digoxin in AF?
Results of a post-hoc analysis of the ENGAGE-AF TIMI 48 trial show the answer could depend on a heart failure Dx.
AACE/ACE Lipid Guidelines Define Extreme CVD Risk
The AACE/ACE 2017 recommendations on lipid management prescribe LDL-C targets, and go far lower than any group has ventured to date.
Metformin Linked to Decreased Mortality in CKD, CHF, and Liver Disease
While the strength of evidence for this "protective" effect is low, observers support further comparative effectiveness research in these patient groups.
Blood Pressure Paradox: Hypertension Associated with Survival in T2D and HF
Patients with comorbid T2D and heart failure may have a "distinct pathophysiology of the heart" say authors of a new study.